Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial

Study Group Investigators:, Elizabeth A. Hahn, Stephanie L. Pugh, Hien L. Lu, Alyssa M. Vela, Erin F. Gillespie, Elizabeth M. Nichols, Jean L. Wright, Shannon M. MacDonald, Oren Cahlon, Carole Baas, Lior Z. Braunstein, L. Christine Fang, Gary M. Freedman, Rachel B. Jimenez, Christy M. Kesslering, Mark V. Mishra, Robert W. Mutter, Nisha Ohri, Lane R. RosenJames J. Urbanic, Reshma Jagsi, Sandra A. Mitchell, Justin E. Bekelman, David Cella, Karen D. Godette, Sagar Patel, Katja M. Langen, Ryan R. Zielan, David DeBlois, Dalong Pang, Sonali Rudra, Sidi Benhabib, Ashish Chawla, Kuanling Chen, Hossein Dadkhah, Lonika Majithia, Avani D. Rao, Lisa Stephenson, Peng Wang, Victoria J. Croog, Heng Li, Karen Smith, Susan Stinson, Amanda J. Walker, Kiran Devisetty, Christian Hyde, Nicholas Depauw, Anuradha Godishala, Alice Ho, Harald Paganetti, Daniel Soto, Giselle Suero-Abreu, Alphonse G. Taghian, Kimberly S. Corbin, Michele Y. Halyard, Amanda Jackson, Xiaoying Liang, Heather Manke, Lisa A. McGee, Deanna H. Pafundi, Nicholas B. Remmes, Dean A. Shumway, Elizabeth S. Yan, Samuel F. Bakhoum, David A. Barron, Michael Bernstein, John J. Cuaron, Laura Dover, Daphna Y. Gelblum, Philip Gilbo, Richard M. Gewanter, David M. Guttman, Linda Hong, Atif Khan, Quincey LaPlant, Justin Mann, Beryl McCormick, Boris A. Mueller, Borys Mychalczak, Dhwani Parikh, Simon N. Powell, Paul B. Romesser, Diana Roth O'Brien, Karen D. Schupak, Annemarie F. Shepherd, Amy Xu, Anthony Yu, Melissa Zinovoy, Jaafar Bennouna, Marcio Fagundes, Joseph Panoff, Maria Amelia Rodrigues, Jen Yu, Choonsik Lee, Chin Cheng Chen, J. Isabelle Choi, Haibo Lin, Adil S. Akthar, Nausheen Akhter, Stephen A. Mihalcik, Mark Pankuch, Preeti K. Parhar, Michael D. Stutz, Arpi D. Thukral, Dennis Mah, Henry K. Tsai, Rebecca Paulus, Bruce G. Haffty, Sharad Goyal, Ning J. Yue, Jared D. Sturgeon, J. Ben Wilkinson, D. Hunter Boggs, Rex A. Cardan, Allison Dalton, Andrew McDonald, Fred Prior, Jyoti S. Mayadev, Vitali Moiseenko, Anya Narezkina, Nicholas Phreaner, Dominique Rash, Tyler Seibert, Catheryn Yashar, Emily C. Daugherty, Anthony Mascia, Sara A. Medek, Teresa Meier, Julie A. Bradley, Natalie Lockney, Raymond B. Mailhot, Nancy Mendenhall, Michael Rutenberg, Eleanor E. Harris, Janice Lyons, Jack J. Hong, Dan K. Kunaprayoon, Sarah A. McAvoy, Mysore Manu Mysore, Kamila A. Nowak Choi, Akshar N. Patel, Melissa A.L. Vyfhuis, Joelle Wilson, Ozer Algan, Yong Chen, Christina E. Henson, Tomas Dvorak, Twyla Willoughby, Omar Zeidan, Abigail T. Berman, Et tsu Chen, Lei Dong, Amanda Driscoll, Steven J. Feigenberg, Ashley Feriozzi, Carolyn Hencek, James D. Kolker, Andre A. Konski, Bonnie Ky, Lilie L. Lin, Kristina L. Novick, Nosheen Reza, Ann Marie Siegal, Sara Tabakha, Neil K. Taunk, Nicholas Wilcox, Wei Zou, Neha Bhooshan, Richard Croley, David C. Weksberg, Neelour Ahmad, Karen E. Hoffman, Melissa M. Joyner, Melissa P. Mitchell, Falk Poenisch, Benjamin D. Smith, Eric A. Strom, Srilakshmi Vallabhaneni, Richard Cheng, Kylie H. Kang, H. Katherine Kim, Janice N. Kim, Waylene A. Wang, Tony Wong, Walter Bosch, Joshua Mitchell, William Straube, Imran Zoberi, Dinu Balanescu, Peter Y. Chen, Joshua T. Dilworth, Xuanfeng Ding, Teodora Donisan, Daniel A. Hamstra, Phuong Daniella Dang, Stanford Katz, Chiachien J. Wang, Wu Terry Wu

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Purpose: Our purpose was to evaluate the measurement properties of patient-reported outcome (PRO) measures used in the ongoing RadComp pragmatic randomized clinical trial (PRCT). Methods and Materials: The deidentified and blinded data set included 774 English-speaking female participants who completed their 6-month posttreatment assessment. Eleven PRO measures were evaluated, including the Trial Outcome Index from the Functional Assessment of Cancer Therapy-Breast (FACT-B), Satisfaction with Breast Cosmetic Outcomes, the BREAST-Q, and selected Patient-Reported Outcomes Measurement Information System (PROMIS) measures. PROs were measured at 3 timepoints: baseline, completion of radiation therapy (RT), and 6 months post-RT. Ten variables were used as validity anchors. Pearson or Spearman correlations were calculated between PROs and convergent validity indicators. Mean PRO differences between clinically distinct categories were compared with analysis of variance methods (known-groups validity). PRO change scores were mapped to change in other variables (sensitivity to change). Results: Most correlations between PROs and validity indicators were large (≥0.5). Mean score for Satisfaction with Breast Cosmetic Outcomes was higher (better) for those with a lumpectomy compared with those with a mastectomy (P < .001). Mean scores for the FACT-B Trial Outcome Index and for PROMIS Fatigue and Ability to Participate in Social Roles and Activities were better for those with good baseline performance status compared with those with poorer baseline performance status (P < .05). At completion of RT and post-RT, mean scores for Satisfaction with Breast Cosmetic Outcomes and BREAST-Q Radiation were significantly different (P < .001) across categories for all Functional Assessment of Chronic Illness Therapy -Treatment Satisfaction – General items. There were medium-sized correlations between change scores for FACT-B Trial Outcome Index, Fatigue, Anxiety, and Ability to Participate in Social Roles and change scores in the Visual Analog Scale. Conclusions: For patients with nonmetastatic breast cancer receiving radiation in the RadComp PRCT, our findings demonstrate high reliability and validity for important PRO measures, supporting their psychometric strength and usefulness to reflect the effect of RT on health-related quality of life.

Original languageEnglish
Pages (from-to)149-161
Number of pages13
JournalInternational Journal of Radiation Oncology Biology Physics
Volume120
Issue number1
DOIs
StatePublished - Sep 1 2024

Fingerprint

Dive into the research topics of 'Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial'. Together they form a unique fingerprint.

Cite this